Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Setanaxib plus Pembrolizumab in Recurrent or Metastatic SCCHN
NCT05323656Phase 2Completed
- Sponsor
- Calliditas Therapeutics AB
- Start
- Apr 2022
- Primary completion
- Feb 2024
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 2, randomised, double-blind trial in head and neck squamous cell carcinoma (HNSCC) comparing Setanaxib + Pembrolizumab with Placebo + Pembrolizumab (2 arms). Primary endpoint: Best Percentage Change in Tumour Size up to 51 weeks. Started Apr 2022; status: completed.
02
Drugs
setanaxib
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT05323656.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05323656.